Emerging agents for metastatic pancreatic cancer: spotlight on early phase clinical trials

Despite the recent development of new chemotherapeutic regimens and combination strategies, metastatic pancreatic cancer (mPC) still shows only a modest response to conventional cytotoxic agents. However, several novel therapeutic agents targeting the unique features of mPC are showing promise in clinical trials.This article reviews the current state of development of new agents targeting various systems and molecular pathways. We searched...